Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Jan;27(1):393-394.
doi: 10.1007/s12094-024-03540-2. Epub 2024 Jul 5.

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish lung cancer group GECP. Controversies and discussion

Arturo Navarro Martín  1 , Nuria Rodriguez de Dios  2 , Jose Luis Lopez Guerra  3 , Felipe Couñago Lorenzo  4
Affiliations
Comment

Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish lung cancer group GECP. Controversies and discussion

Arturo Navarro Martín et al. Clin Transl Oncol. 2025 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Human and animal rights: This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent: The authors declare that they have no conflict of interest.

Comment on

  • Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.
    Ospina AV, Bolufer Nadal S, Campo-Cañaveral de la Cruz JL, González Larriba JL, Macía Vidueira I, Massutí Sureda B, Nadal E, Trancho FH, Álvarez Kindelán A, Del Barco Morillo E, Bernabé Caro R, Bosch Barrera J, Calvo de Juan V, Casal Rubio J, de Castro J, Cilleruelo Ramos Á, Cobo Dols M, Dómine Gómez M, Figueroa Almánzar S, Garcia Campelo R, Insa Mollá A, Jarabo Sarceda JR, Jiménez Maestre U, López Castro R, Majem M, Martinez-Marti A, Martínez Téllez E, Sánchez Lorente D, Provencio M. Ospina AV, et al. Clin Transl Oncol. 2024 Jul;26(7):1647-1663. doi: 10.1007/s12094-024-03382-y. Epub 2024 Mar 26. Clin Transl Oncol. 2024. PMID: 38530556 Free PMC article. Review.

References

    1. Ospina AV, Bolufer Nadal S, De La Campo-Cañaveral Cruz JL, González Larriba JL, Macía Vidueira I, Massutí Sureda B, Nadal E, Trancho FH, Álvarez Kindelán A, Del Barco Morillo E, Bernabé Caro R, Bosch Barrera J, De Calvo Juan V, Casal Rubio J, De Castro J, Cilleruelo Ramos Á, Cobo Dols M, Dómine Gómez M, Figueroa Almánzar S, Garcia Campelo R, Insa Mollá A, Jarabo Sarceda JR, Jiménez Maestre U, López Castro R, Majem M, Martinez-Marti A, Martínez Téllez E, Sánchez Lorente D, Provencio M. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP. Clin Transl Oncol. 2024. https://doi.org/10.1007/s12094-024-03382-y . - DOI - PubMed - PMC
    1. Dickhoff C, Heineman D, Schneiders F, Houda I, Veltman J, Hashemi S, Fransen M, Radonic T, Bartelink I, Meijboom L, Oprea-Lager D, Bouwhuis N, De Gruijl T, Senan S, Bahce I. OA06.04 surgery after neoadjuvant immuno-chemoradiotherapy in (borderline) Resectable NSCLC: results from the INCREASE Trial. J Thorac Oncol. 2023;18:S56–7. https://doi.org/10.1016/j.jtho.2023.09.045 . - DOI
    1. Rothschild SI, Zippelius A, Eboulet EI, Savic Prince S, Betticher D, Bettini A, Früh M, Joerger M, Lardinois D, Gelpke H, Mauti LA, Britschgi C, Weder W, Peters S, Mark M, Cathomas R, Ochsenbein AF, Janthur W-D, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39:2872–80. https://doi.org/10.1200/JCO.21.00276 . - DOI
    1. Dickhoff C, Heineman DJ, Bahce I, Senan S. Unresectable stage III NSCLC can be reevaluated for resectability after initial treatment. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2023;18:1124–8. https://doi.org/10.1016/j.jtho.2023.06.002 . - DOI
    1. Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2023;18:181–93. https://doi.org/10.1016/j.jtho.2022.10.003 . - DOI